Rupprecht C E, Hanlon C A, Niezgoda M, Buchanan J R, Diehl D, Koprowski H
Centres for Disease Control, Viral and Rickettsial Zoonoses Branch, Atlanta, Georgia 30333.
Onderstepoort J Vet Res. 1993 Dec;60(4):463-8.
With the advancement of recombinant DNA techniques, a number of potent biologicals are available for the oral vaccination of free-ranging animals. Once oral immunogenicity and vaccine safety have been demonstrated, efficacy then becomes of paramount importance. Classical assessment of efficacy is conducted under carefully controlled laboratory conditions, whereas efficacy of oral wildlife rabies vaccination programs, to date, have been assessed by the lack (or occurrence) of field cases of rabies in a vaccinated area. This communication describes an intermediate vaccine efficacy strategy in which self-vaccinated, free-ranging animals from a study site were captured seven months after vaccine-laden bait distribution for laboratory rabies challenge. This technique is specifically reviewed in the context of available recombinant products for the consideration of extension towards dog rabies control.
随着重组DNA技术的进步，有多种强效生物制品可用于对自由放养动物进行口服疫苗接种。一旦证明了口服免疫原性和疫苗安全性，那么效力就变得至关重要。经典的效力评估是在严格控制的实验室条件下进行的，而迄今为止，口服野生动物狂犬病疫苗接种计划的效力是通过接种疫苗地区狂犬病野外病例的有无（或发生情况）来评估的。本通讯描述了一种中间疫苗效力策略，即在分发含疫苗诱饵七个月后，捕获来自研究地点的自行接种的自由放养动物，进行实验室狂犬病攻毒试验。本文结合现有的重组产品对该技术进行了专门综述，以供考虑将其推广用于犬狂犬病控制。
